@thelancetoncol
The Lancet Oncology is the global leader in clinical oncology publishing peer-reviewed research and reviews, comment, news, and Commissions. IF=35·9. 🌐 https://www.thelancet.com/journals/lanonc/home
In our March Editorial, we discuss England's National Cancer Plan, launched on Feb 4.
The plan sets out ambitious targets, but will these be met?
Read England's National Cancer Plan: hollow promises? here:🖱️https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00077-X/fulltext#f10
🎧 Our March podcast: We talk to Dylan Graetz and Erica Kaye
@stjuderesearch.bsky.social about qualitative research in oncology
thelancet.com/multimedia/p...
Follow In Conversation With
Spotify: open.spotify.com/show/3JOj0Cl...
Apple: podcasts.apple.com/us/podcast/t...
🆕Our March issue is live!
📊Articles: #prostatecancer, #breastcancer, #melanoma, and #brachytherapy
📰Reviews: #ESTRO concensus on RT for more efficacious novel anticancer drugs + a expert consensus on oligometastatic pancreatic cancer
www.thelancet.com/issue/S1470-...
A clinical trial from @thelancetoncol.bsky.social explores whether advanced PET imaging improves outcomes over standard MRI for guiding re-irradiation in recurrent glioblastoma.
It aligns with our journal's focus on how imaging influence treatment & patient lives
🔓https://bit.ly/thelancet-lanonc-642
We are happy to be media partners with the European Association for Cancer Research (EACR) for the #EACR2026 Congress: Innovative Cancer Science in Budapest, Hungary; June 8–11, 2026
Submit your abstract by March 4, 2026: 2026.eacr.org
🔴Online now: Ultra-hypofractionated versus conventionally fractionated radiotherapy for localised #prostatecancer (HYPO-RT-PC): 10-year outcomes of an open-label, randomised, phase 3, non-inferiority trial
thelancet.com/journals/lan...
(CAR) T-cell therapy. Composite coloured scanning electron micrograph (SEM) of T-cells (small round) and an apoptotic cervical cancer cell (Hela). Copyright: STEVE GSCHMEISSNER / SCIENCE PHOTO LIBRARY
On #WorldCancerDay, stay up to date with the latest oncology content published across The Lancet Group.
Explore our Specialty Collection: spkl.io/63327AsDNU
🆕 Greater transparency for oncology clinical trials reporting
Chief Editors of The Lancet’s specialty journals discuss enhanced scrutiny in the reporting of oncology clinical trials
Read here: thelancet.com/journals/lan...
✏️February's Editorial - Cancer: another casualty of geopolitical unrest?
We discuss the deprioritisation of health care during geopolitical instability
www.thelancet.com/journals/lan...
🆕Our Feb issue is live!
📉Articles: #NSCLC, #glioblastoma, #prostatecancer, #oesophagealcancer, and #coloncancer
📰Reviews: International Multidisciplinary Consensus Group for Malignant Spinal Cord Compression AND ReCOG consensus on multiple courses of RT
thelancet.com/issue/S1470-...
🆕 “In this Viewpoint, we argue that trusted, hyperlocal, and globally present CHWs are a largely overlooked workforce in tackling the climate crisis, despite already doing work in adapting to and mitigating climate change.”
Read the full Viewpoint now ➡️ www.thelancet.com/journals/lan...
Join our webinar on Feb 4, Improving Outcomes for Children with Serious Illness through Applied Qualitative Research
Hosted by @stjuderesearch.bsky.social in collaboration with @thelancetoncol.bsky.social@thelancethaem.bsky.social @eclinicalmed.bsky.social
stjudeglobal.zoom.us/meeting/regi...
As part of The Lancet Group’s partnership with
IARC WHO for the #IARC60 Cancer Research into Action Conference, 19-21 May, 2026, @eclinicalmed.bsky.social will be publishing a best of special issue of conference abstracts
Submit your abstract by 19 Jan iarc2026conf.iarc.who.int/en/abstracts...
@thelancetoncol.bsky.social, @thelancetph.bsky.social, @eclinicalmed.bsky.social are excited to partner with IARC for: #IARC60 Cancer Research into Action Conference Lyon, France, 19-21 May
Submit your abstract by 19 Jan: iarc2026conf.iarc.who.int/en/abstracts...
For more: iarc2026conf.iarc.who.int
🔴Online: Aumolertinib as adjuvant therapy in resected EGFR-mutated #NSCLC (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial
📉Article thelancet.com/journals/lan...
✏️Comment thelancet.com/journals/lan...
Research in context panel for Lancet paper "Proton versus photon radiotherapy for patients with oropharyngeal cancer in the USA: a multicentre, randomised, open-label, non-inferiority phase 3 trial" Copyright: 2025 Elsevier Ltd. All rights are reserved.
Proton versus photon radiotherapy for patients with oropharyngeal cancer in the USA: a multicentre, randomised, open-label, non-inferiority phase 3 trial spkl.io/63327AmhOT
🔴Online now: Cilta-cel in lenalidomide-refractory #multiplemyeloma (CARTITUDE-4): an updated analysis including OS from an open-label, multicentre, randomised, phase 3 trial
thelancet.com/journals/lan...
🔴Online first: A new Comment from Clare Turnbull and colleagues on the PATHFINDER2 study of GRAIL's Galleri multicancer detection blood test
thelancet.com/journals/lan...
✏️Our Jan 2026 Editorial: Cancer consequences of the HIV funding crisis
"Beyond the already devastating impact on the global burden of HIV, the disruptions seen in 2025 could have consequences beyond HIV and AIDS alone..."
www.thelancet.com/journals/lan...
🆕Our Jan 26 issue!
📈Articles: #endometrialcancer, #NSCLC, #glioma, #prostatecancer, #oesophagealcancer, #pancreaticcancer
📄Reviews: Framework for glioma surgery by PIONEER and RANO resect
🖱️https://www.thelancet.com/issue/S1470-2045(25)X0013-9
2026 cover artist: J Specht (IG@ ju.liaspecht)
🔴Online now: FET-PET-guided versus contrast-enhanced T1-weighted MRI-guided re-irradiation in patients with recurrent #glioblastoma (GLIAA/NOA-10 ARO2013-01): a multicentre, open-label, randomised trial
www.thelancet.com/journals/lan...
The Call for Abstracts for the #IARC60 Cancer Research into Action Conference, in Lyon, France, 19-21 May, 2026 is open
Deadline for abstract submission: 19 Jan 2026
iarc2026conf.iarc.who.int/en/abstracts...
More info on the conference website: iarc2026conf.iarc.who.int
🎉We're excited to announce our partnership with
#IARCWHO for the #IARC60 Cancer Research into Action Conference, in Lyon, France, 19-21 May, 2026!🎉
Accepting abstract until 19 Jan 2026
iarc2026conf.iarc.who.int/en/abstracts...
More info on the conference website: iarc2026conf.iarc.who.int
@thelancetoncol.bsky.social's highlights from the San Antonio Breast Cancer Symposium 2025, #SABCS25
Including trials ELEVATE, ASCENT-07, EPIK-B5, and DETECT V
thelancet.com/journals/lan...
✏️This month's Editorial: Making prostate cancer screening fit for purpose
www.thelancet.com/journals/lan...
🚨Our Dec issue is live! - thelancet.com/issue/S1470-...
📊Articles: #lungcancer, #breastcancer, #hepatocellularcarcinoma, #rectalcancer, #glioma
📑Reviews including neurocognitive outcomes in patients with brain metastases AND SISAQOL-IMI consensus guidelines on PROs in trials
🔴Online: Artificial intelligence and radiologists in #pancreaticcancer detection using standard of care CT scans (PANORAMA): an international, paired, non-inferiority, confirmatory, observational study
thelancet.com/journals/lan...
Check out London Global Cancer Week #LGCW2025, running Nov 24 to Nov 28.
www.lgcw.org.uk/lgcw-2025/
It's a pleasure for @thelancetoncol.bsky.social to sponsor another year!
News
🗞️Government shutdown and Medicare changes impact cancer care in the USA, reported by Sharmila Devi
www.thelancet.com/journals/lan...
🗞️More e-cigarette users than cigarette smokers for the first time in the UK, reported by Manjulika Das
www.thelancet.com/journals/lan...
📊Online now: Effectiveness of NELSON versus PLCOm2012 #lungcancer screening eligibility criteria in Germany (HANSE): a prospective cohort study
thelancet.com/journals/lan...
✏️Comment: Defining eligibility for lung cancer screening based on individual risk
thelancet.com/journals/lan...